Pandey S, Singh A, Yang G, d'Andrea FB, Jiang X, Hartman TE, Mosior JW, Bourland R, Gold B, Roberts J et al..
2021.
Characterization of Phosphopantetheinyl Hydrolase from Mycobacterium tuberculosis.. Microbiol Spectr. 9(2):e0092821.
Honjo K, Russell RM, Li R, Liu W, Stoltz R, Tabengwa EM, Hua Y, Prichard L, Kornbrust AN, Sterrett S et al..
2021.
Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.. Cell Rep Med. 2(1):100164.
Zhan W, Zhang H, Ginn J, Leung A, Liu YJ, Michino M, Toita A, Okamoto R, Wong T-T, Imaeda T et al..
2021.
Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.. Angew Chem Int Ed Engl. 60(17):9279-9283.
Lee BShi, Hards K, Engelhart CA, Hasenoehrl EJ, Kalia NP, Mackenzie JS, Sviriaeva E, Chong SMin Sheril, Manimekalai MSony S, Koh VH et al..
2021.
Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.. EMBO Mol Med. 13(1):e13207.
Zhang H, Hsu H-C, Kahne SC, Hara R, Zhan W, Jiang X, Burns-Huang K, Ouellette T, Imaeda T, Okamoto R et al..
2021.
Macrocyclic Peptides that Selectively Inhibit the Mycobacterium tuberculosis Proteasome.. J Med Chem. 64(9):6262-6272.
Saito K, Mishra S, Warrier T, Cicchetti N, Mi J, Weber E, Jiang X, Roberts J, Gouzy A, Kaplan E et al..
2021.
Oxidative damage and delayed replication allow viable Mycobacterium tuberculosis to go undetected.. Sci Transl Med. 13(621):eabg2612.
Saito K, Mishra S, Warrier T, Cicchetti N, Mi J, Weber E, Jiang X, Roberts J, Gouzy A, Kaplan E et al..
2021.
Oxidative damage and delayed replication allow viable Mycobacterium tuberculosis to go undetected.. Sci Transl Med. 13(621):eabg2612.
Racine-Brzostek SE, Yang HS, Jack GA, Chen Z, Chadburn A, Ketas TJ, Francomano E, Klasse PJ, Moore JP, McDonough KA et al..
2021.
Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health.. J Clin Endocrinol Metab. 106(5):e2025-e2034.
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..
2021.
Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Liu W, Russell RM, Bibollet-Ruche F, Skelly AN, Sherrill-Mix S, Freeman DA, Stoltz R, Lindemuth E, Lee F-H, Sterrett S et al..
2021.
Predictors of Nonseroconversion after SARS-CoV-2 Infection.. Emerg Infect Dis. 27(9):2454-2458.
Giardina SF, Valdambrini E, J Warren D, Barany F.
2021.
PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance.. Curr Cancer Drug Targets. 21(4):306-325.
Jurgens EMatthew, Ketas TJoseph, Zhao Z, Satlin MJoseph, Small CButkus, Sukhu A, Francomano E, Klasse PJohan, Garcia A, Nguyenduy E et al..
2021.
Serologic response to mRNA COVID-19 vaccination in lymphoma patients.. Am J Hematol. 96(11):E410-E413.
Ray PC, Huggett M, Turner PA, Taylor M, Cleghorn LAT, Early J, Kumar A, Bonnett SA, Flint L, Joerss D et al..
2021.
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth.. ACS Omega. 6(3):2284-2311.
Barbet G, Nair-Gupta P, Schotsaert M, Yeung ST, Moretti J, Seyffer F, Metreveli G, Gardner T, Choi A, Tortorella D et al..
2021.
TAP dysfunction in dendritic cells enables noncanonical cross-presentation for T cell priming.. Nat Immunol. 22(4):497-509.